Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia [Yahoo! Finance]
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: Yahoo! Finance
Ascendis Pharma A/S (NASDAQ:ASND) executives outlined plans for the U.S. launch of YUVIWEL following FDA approval, describing the product as the first once-weekly treatment for children with achondroplasia and emphasizing its label, clinical profile, and expected near-term commercialization steps. FDA approval details and clinical basis Chief Executive Officer Jan Mikkelsen said the FDA approval of YUVIWEL marks the company's third FDA-approved drug. Management stated that the approval was based on data from three randomized, double-blind, placebo-controlled trials, including the pivotal ApproaCH trial. ? Defense Stocks Are Soaring—AeroVironment's Earnings Could Close the Gap 3 Oversold Stocks with Big RSI Rebound Potential Chief Medical Officer Amy Xu reviewed efficacy data from ApproaCH, stating that superiority versus placebo was demonstrated for the primary endpoint of annualized growth velocity (AGV) at week 52. She said children treated with navepegritide achieved an
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma A/S (ASND) was given a new $332.00 price target by Stifel Nicolaus.MarketBeat
- Ascendis Wins FDA Approval For Rare Disease Therapy [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Royal Bank Of Canada.MarketBeat
- Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript [Seeking Alpha]Seeking Alpha
ASND
Earnings
- 2/11/26 - Miss
ASND
Sec Filings
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- 3/2/26 - Form 144
- ASND's page on the SEC website